N-Cyanomethyl-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide | 552334-87-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: N-Cyanomethyl-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide
• 英文别名: N-[2-(Methylsulfonyl)ethyl]-N-(cyanomethyl)trifluoroacetamide；N-(cyanomethyl)-2,2,2-trifluoro-N-(2-methylsulfonylethyl)acetamide
• CAS: 552334-87-9
• 化学式: C₇H₉F₃N₂O₃S
• 分子量: 258.221
• InChiKey: HLXKAJMRANUPQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  86.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-Cyanomethyl-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide 在 sodium hydroxide 、 硫化氢 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4-(3-fluoro-benzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine
  参考文献：
  名称：

  Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

  摘要：

  We have identified a novel class of 6-thiazolylquinazolines as potent and selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity, with IC50 values in the nanomolar range. These compounds inhibited the growth of both EGFR (HN5) and ErbB-2 (BT474) over-expressing human tumor cell lines in vitro. Using xenograft models of the same cell lines. we found that the compounds given orally inhibited in vivo tumor growth significantly compared with control animals. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01047-8
• 作为产物：
  描述：

  2-((2-(甲硫基)乙基)氨基)乙腈 在 Oxone 、 sodium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-Cyanomethyl-2,2,2-trifluoro-N-(2-methanesulfonyl-ethyl)-acetamide
  参考文献：
  名称：

  Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

  摘要：

  We have identified a novel class of 6-thiazolylquinazolines as potent and selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity, with IC50 values in the nanomolar range. These compounds inhibited the growth of both EGFR (HN5) and ErbB-2 (BT474) over-expressing human tumor cell lines in vitro. Using xenograft models of the same cell lines. we found that the compounds given orally inhibited in vivo tumor growth significantly compared with control animals. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01047-8

文献信息

• HETEROCYCLIC COMPOUNDS
  申请人：CARTER Clive Malcolm

  公开号：US20070238875A1

  公开（公告）日：2007-10-11

  A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH 2 (III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R 1 by replacement of the leaving group L′.

  一种制备化合物(I)的方法，包括以下步骤：（a）将式为(II)的化合物与式为(III)的化合物UNH2(III)反应，其中L和L'是适当的离去基团，以制备式为(IV)的化合物；随后(b)通过替换离去基团L'来取代基团R1。
• BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
  申请人：GlaxoSmithKline LLC

  公开号：US20150065527A1

  公开（公告）日：2015-03-05

  A pharmaceutical formulation comprising the compound of formula

  一种药物配方，其中包含化学式的化合物。
• Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
  申请人：Carter Malcom Clive

  公开号：US20100120804A1

  公开（公告）日：2010-05-13

  A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH 2 (III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R 1 by replacement of the leaving group L′.

  一种制备化合物(I)的方法，包括以下步骤：(a) 将式为(II)的化合物与式为(III)的化合物UNH2(III)反应，其中L和L'是合适的离去基团，制备出式为(IV)的化合物；随后(b)通过取代离去基团L'来替换基团R1。
• Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US20130310562A1

  公开（公告）日：2013-11-21

  A pharmaceutical formulation comprising the compound of formula

  一种药物配方，包含公式的化合物。
• US8513262B2
  申请人：——

  公开号：US8513262B2

  公开（公告）日：2013-08-20